STOCK TITAN
  1. Home
  2. Sec-filings
  3. STOK
  4. [Form 4] Stoke Therapeutics, Inc. Insider Trading Activity

STOK Form 4: 570,000 options at $30.5; 380,000 RSUs granted

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Stoke Therapeutics (STOK) reported insider equity grants to its Chief Executive Officer and Director. On 10/08/2025, the reporting person received a stock option to buy 570,000 shares at $30.5 per share, expiring on 10/07/2035. The option vests as to 1/4 on 10/06/2026, then 1/48 monthly thereafter, subject to continued service.

The filing also reports 380,000 RSUs, each representing one share of common stock, vesting 1/4 annually on the sixth day of October, with the first tranche on 10/06/2026, subject to continued service. Ownership form for both awards is listed as direct.

Positive

  • None.

Negative

  • None.
Insider SMITH IAN F
Role Chief Executive Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 570,000 $0.00 --
Grant/Award Restricted Stock Units 380,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 570,000 shares (Direct); Restricted Stock Units — 380,000 shares (Direct)
Footnotes (1)
  1. The option shall vest as to 1/4 of the total award on October 6, 2026, with an additional 1/48 of the total award vesting monthly thereafter, subject to the reporting person's continued service to the Issuer on each vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The award shall vest as to 1/4 of the total award annually on the sixth calendar day of October, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vesting on October 6, 2026.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
SMITH IAN F
(Last) (First) (Middle)
C/O STOKE THERAPEUTICS, INC.
45 WIGGINS AVENUE
(Street)
BEDFORD MA 01730
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/08/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $30.5 10/08/2025 A 570,000 (1) 10/07/2035 Common Stock 570,000 $0 570,000 D
Restricted Stock Units (2) 10/08/2025 A 380,000 (3) 10/06/2029 Common Stock 380,000 $0 380,000 D
Explanation of Responses:
1. The option shall vest as to 1/4 of the total award on October 6, 2026, with an additional 1/48 of the total award vesting monthly thereafter, subject to the reporting person's continued service to the Issuer on each vesting date.
2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
3. The award shall vest as to 1/4 of the total award annually on the sixth calendar day of October, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vesting on October 6, 2026.
/s/ Jonathan Allan, Attorney-in-Fact 10/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did STOK disclose in this Form 4?

Grants on 10/08/2025 of a 570,000-share stock option at $30.5 per share (expiring 10/07/2035) and 380,000 RSUs to the CEO/Director.

What is the vesting schedule for the 570,000 stock options at STOK?

The option vests 1/4 on 10/06/2026 and then 1/48 monthly thereafter, subject to continued service.

How do the 380,000 RSUs for STOK vest?

They vest 1/4 annually on the sixth day of October, with the first tranche on 10/06/2026, subject to continued service.

What is the exercise price and expiration for the STOK stock option grant?

The exercise price is $30.5 per share, and the option expires on 10/07/2035.

What does each STOK RSU represent?

Each RSU represents a contingent right to receive one share of STOK common stock upon settlement.

How is ownership reported for these STOK awards?

Both the option and RSUs are reported as Direct (D) ownership.